The Evidence

Predictive coding, neurotags and MCS: what neuroscience can explain — and what it cannot

Predictive coding, neurotags, somatic tracking, and neuroplasticity can help explain how expectation, learning, and threat processing modify an established response. They do not establish the origin of consensus-defined MCS, and chronic-pain treatment evidence cannot simply be imported and called MCS treatment evidence. Modulation is not causation, and symptom relief is not automatically restored chemical tolerance.

The brain predicts, learns, and changes sensory gain. Those facts are relevant to amplification, context, and conditioned responses after illness begins. They do not establish that a prediction error created MCS, and they do not justify treating protective exposure vigilance as proof of psychological causation.

The predictive brain is real

The brain does not passively record the outside world. It combines incoming sensory signals with prior experience, context and expectation. That predictive architecture helps us react quickly to danger and make sense of incomplete information.

"Neurotag" is a less formal term used in some pain and mind-body communities for a network or pattern associated with a particular sensation or response. Whether or not that word is used, the underlying idea - neural circuits strengthen with repeated activation and learning - is basic neuroplasticity.

Why this matters to MCS

Once a person has repeatedly become ill around a chemical odor or environment, the nervous system can learn that context. Expectation can alter attention, autonomic output, perception and symptom intensity. Provocation studies in MCS show that awareness of active versus sham exposure can influence reactions, which is evidence that prediction and expectation can become part of the response.

Exposure vigilance comes after repeated reactions in many patient stories

Repeated physical reactions can teach a person to watch environments closely. That protective attention is exposure vigilance. It can coexist with predictive processing and conditioned learning, but it should not be collapsed into them. A person may become vigilant because exposures repeatedly made them ill; the vigilance did not necessarily create the first reaction.

That chronology is exactly why the Canary Registry asks when symptoms began, when the person first suspected an environmental cause, and whether reactions occurred before a trigger was recognized.

That is important. It means an accurate MCS model should leave room for learned amplification rather than pretending every later reaction is a simple readout of chemical concentration.

The crucial distinction: maintenance is not initiation

The leap occurs when a valid principle of prediction is turned into a complete origin story: "The brain predicts danger, therefore predictive error caused MCS." That conclusion is not established.

If illness began after an environmental exposure - especially before the patient knew or believed that exposure was involved - later conditioning cannot travel backward in time and explain the onset. Prediction may become a maintenance or amplification layer on top of an environmentally initiated physiological change.

Sarno, Gordon, Schubiner, and the chronic-pain evidence

This is where work by John Sarno, Alan Gordon, Howard Schubiner and related clinicians becomes relevant but must be kept in its evidence lane. Pain Reprocessing Therapy has strong randomized evidence in primary chronic back pain. In a 151-person trial, many participants experienced major and durable pain reductions, and later follow-up showed benefits persisting for years.

That is powerful evidence that some chronic pain can be maintained by reversible brain-based processes. It is not an MCS treatment trial. Chronic pain and MCS may share mechanisms of sensory gain or threat learning, but one cannot be substituted for the other without direct evidence.

Somatic tracking and exposure: potentially useful tools, not proof of cause

Somatic tracking teaches neutral observation of sensations while reducing fear and danger interpretation. In the right condition, that can weaken learned threat associations. A person with MCS may also benefit in fear, coping or symptom amplification from similar nervous-system work.

But deliberately smelling a trigger while sending "safety signals" is not automatically safe or therapeutic for consensus-defined MCS. Exposure work must distinguish a conditioned cue from an exposure that repeatedly produces physiological illness. Controlled MCS evidence has not shown that thought-based retraining reliably restores chemical tolerance.

What the registry is answering

The retraining module should identify the exact method used - DNRS, Gupta/AIR, somatic tracking, PRT-style work, mindfulness, CBT or another program - and separate outcomes: fear, coping, sleep, symptom intensity, function and actual tolerance of previously reproducible chemical triggers.

It should also ask what changed at the same time: housing, mold, occupational exposure, medication, diet and overall exposure burden. That is how we distinguish a compelling story from a causal treatment signal.

Where we stand

Predictive coding and neuroplasticity belong in the MCS framework. They provide plausible mechanisms for amplification, generalization, context effects and possibly recovery in some people.

They do not replace the environmental-initiation evidence, and they do not establish thought as the root cause. The correct model is layered: what starts the illness, what changes biologically, what gets learned afterward, and what must reverse for tolerance to return.

We followed the evidence. Here’s where it leads →

Sources

Sources

1Moseley GL, Butler DS — neurotags and pain neuroscience.
2Ashar YK et al. Pain Reprocessing Therapy RCT in chronic back pain. JAMA Psychiatry 2022.
3Schubiner H; Gordon A — clinical neural-circuit approaches.
4Hauge CR, Rasmussen A, Piet J, et al. Mindfulness-based cognitive therapy for multiple chemical sensitivity: a randomised controlled trial with 1 year follow-up. Journal of Psychosomatic Research. 2015;79(6):628–634. PMID: 26311155.
5Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: a systematic review of provocation studies. Journal of Allergy and Clinical Immunology. 2006;118(6):1257–1264. PMID: 17137865.
62. Ashar YK, Gordon A, Schubiner H, et al. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 34586357. https://pubmed.ncbi.nlm.nih.gov/34586357/
73. Ashar YK, et al. Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: 5-Year Follow-Up. JAMA Psychiatry. 2025. PMID: 40736996. https://pubmed.ncbi.nlm.nih.gov/40736996/
← Back to MCSDisability.com
↑